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Movement of lung tumors
with respect to the bony
anatomy may lead to over-
dosage of organs at risk. In
this study the potential
benefit of dose-guided
radiotherapy for non-small-
cell lung cancer patients
treated with stereotactic
body radiotherapy was
investigated. The V100% of
the internal target volume is
already sufficient before
position correction in the
majority of cases. The Dmax
in organs at risk during
treatment differed up to 10%
with respect to the treatment
plan. These results show that
dose-guided radiotherapy
can be a valuable addition to
image-guided radiotherapy.Reprint requests to: Arjan Bel, Ph.D., A
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Open access undPurpose: To determine whether dose-guided radiotherapy (i.e., online recalculation and evalu-
ation of the actual dose distribution) can improve decision making for lung cancer patients
treated with stereotactic body radiotherapy.
Methods and Materials: For this study 108 cone-beam computed tomography (CBCT) scans of
10 non-small-cell lung cancer patients treated with stereotactic body radiotherapy were analyzed
retrospectively. The treatment plans were recalculated on the CBCT scans. The V100% of the
internal target volume (ITV) and Dmax of the organs at risk (OARs) were analyzed. Results from
the recalculated data were compared with dose estimates for target and OARs by superposition
of the originally planned dose distribution on CBCT geometry (i.e., the original dose distribution
was assumed to be spatially invariant).
Results: Before position correction was applied the V100% of the ITV was 100% in 65% of the
cases when an ITVePTV margin of 5 mm was used and 52% of the cases when a margin of 3
mm was used. After position correction, the difference of Dmax in the OARs with respect to the
treatment plan was within 5% in the majority of the cases. When the dose was not recalculated
but estimated assuming an invariant dose distribution, clinically relevant errors occurred in both
the ITV and the OARs.
Conclusion: Dose-guided radiotherapy can be used to determine the actual dose in OARs when
the target has moved with respect to the OARs. When the workflow is optimized for speed, it can
be used to prevent unnecessary position corrections. Estimating the dose by assuming an
invariant dose instead of recalculation of the dose gives clinically relevant errors.
 2012 Elsevier Inc.
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biologically effective dose in a small number of treatment frac-
tions. Stereotactic body radiotherapy is often used in patients with
Stage I/II non-small-cell lung cancer (NSCLC) who are unfit or
unwilling to undergo surgery. Several studies have reported local
control rates above 85% (1e3). A major problem in SBRT for
lung tumors is the interfraction variation in the time-averaged
tumor position relative to the bony anatomy: the baseline shift
(4) (Fig. 1a). The interfraction variation of the tumor position is
corrected by adapting the patient position, but this may result in
a higher dose in an organ at risk (OAR). To prevent overdosage to
OARs, margins are drawn around the OARs to create a planning
organ at risk volume (PRV).
In some cases the displacement of the tumor with respect to an
OAR exceeds the size of the safety margin. Currently there is no
clear protocol for such cases. Moreover, weight loss or a change in
patient position that cannot be corrected can affect the dose
distribution as a whole (Fig. 1b). When the dose distribution in the
current situation can be evaluated online, an objective and well-
considered decision can be made about how to proceed.
The goal of this study was to investigate the potential benefits
of dose-guided radiotherapy (DGRT) (i.e., online recalculation and
evaluation of the dose distribution using a [near] real-time image
of the patient anatomy). This is done by retrospectively recalcu-
lating the dose distribution on the cone-beam computed tomog-
raphy (CBCT) scans of 10 NSCLC patients treated with SBRT.
Methods and Materials
Patients
Ten patients treated in our department with SBRT in the period
October 2009eMay 2010 were included in this study. Planning
CTs were acquired with a GE Lightspeed RT16 scanner (General
Electric Healthcare, Waukesha, WI) with the patient in the supine
position. The patients were lying on a polyurethane foam support
cushion (Accessories RadioTherapy, Eindhoven, The
Netherlands). The patient’s head and arms were positioned on
a Posirest-2 (Civco, Kalona, IA).Fig. 1. Two cases in which an online dose calculation would be helpfu
the cone-beam CT. (a) Tumor has moved with respect to the bony anato
risk may be different from the treatment plan. (b) Shape of the patientTarget definition and treatment planning
The internal target volume (ITV) was delineated on a slow CT
scan, and a positron emission tomography (PET)-CT was used to
guide the delineation. An ITVeplanning target volume (PTV)
margin of 5 mm was used, according to our clinical protocol. For
comparison, a second plan was made using an ITVePTV margin
of 3 mm, because Hurkmans et al. (5) recommended using
a margin of 3e5 mm. The OARs (spinal cord, esophagus, heart,
and trachea) were also defined as recommended (5). An
OARePRV margin of 10 mm was used. Note that this PRV
margin was not used in the traditional way (i.e., to compensate for
movement of the OAR itself) but to compensate for a possible
baseline shift of the target with respect to the OARs.
The treatment plans and the recalculations on CBCT were
made with Oncentra v4.0 (Nucletron, Veenendaal, The
Netherlands) using the collapsed cone algorithm (6). Each plan
consisted of 12e15 beams of 6 MV, which were noncoplanar. The
beam angles were optimized to avoid the critical structures as
much as possible. The prescribed dose was either 3  18 Gy (3
patients) or 5  11 Gy (7 patients). The requirements of the
treatment plan were that 95% of the PTV received at least the
prescribed dose and that 100% of the ITV received 100% of the
prescribed dose. The constraints for the OARs depended on the
fractionation scheme, as described in the recommendations of
Hurkmans et al. (5). For the 3  18-Gy scheme the maximum
doses were 18 Gy to the spinal cord, 24 Gy to the esophagus and
the heart, and 30 Gy to the trachea. For the 5  11-Gy scheme the
maximum doses were 25 Gy to the spinal cord, 27 Gy to the
esophagus and the heart, and 32 Gy to the trachea.
CBCT scans
Before treatment a CBCT was made using the Synergy system
(Elekta, Crawley, United Kingdom) and registered with XVI
release 3.5 (Elekta). All CBCT scans were made using the same
protocol: M20 collimator, 360 scan, 120 kV, and a bow-tie filter
(7). The CBCT and planning CT scans were registered on the basis
of a grey value match of a volume that contained the tumor and
a small part of the surrounding tissue. The rotations were con-
verted into translations with the correction reference point in the
center of the ITV.l. Purple scan represents the planning CT and green scan represents
my. When position correction is applied the dose in the organs at
has changed, which may cause a change in dose distribution.
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executed without a threshold. After execution of the required
correction, a new CBCT was made for verification. If the vector
length of the registration result was smaller than 3 mm in the
verification scan, the radiation was started. Otherwise a second
correction was executed and a new CBCT scan was made.
Halfway through treatment, another CBCT was made to check
whether the patient had moved. If the registration result exceeded
the threshold of 3 mm, the position of the patient was corrected
and another CBCT scan was made to verify this correction.
In this study only combinations of scans made before and after
application of a correction were considered. Hence, the scans that
were made halfway through treatment were only taken into
account if the registration result exceeded the threshold. A total of
108 CBCT scans were used for this study: 54 before and 54 after
applying a position correction. Eighty-two scans were taken at the
start of the treatment and 26 halfway.
The delineated structures were copied onto the CBCT scan
from the planning CT scan, with the target shifted according to the
tumor registration and the OARs shifted according to a bone
match. The body contour was not copied but automatically
delineated on the CBCT scans (8).
Copying the OARs from the planning CTand shifting them with
the bone match is an approximation of the position of those struc-
tures. For the spinal cord, this approximation is obviously accurate.
For the esophagus and the trachea there might be a deviation with
respect to the real position. However, delineation of the structures is
time consuming and therefore unrealistic for the purpose of DGRT.
Moreover, the poor soft-tissue contrast of the CBCT is likely to
cause delineation errors. To give an indication of the uncertainty of
the dose in those organs, we studied a worst-case scenario. We
selected for each patient the scan of the first fraction, after correc-
tion.Wemoved the esophagus or the trachea, whichever was closest
to the target, 5 mm toward the target. The difference of the
maximum dose of the moved and the original structure is reported.
Dose calculation
The CBCTs were exported from XVI with adapted Digital Imaging
and Communications in Medicine (DICOM) export settings (i.e.,
the export parameter RescaleIntercept in the configuration file sri.ini
was changed to1024 to give the grey values of the CBCT the same
range as Hounsfield units (HUs)). A preliminary study has
demonstrated that using these export settings and a standard CT
Hounsfield unit density table yielded a reliable dose distribution for
CBCT scans made with the Elekta Synergy System. In this study,
dose distributions of several plans were calculated on the CBCT of
a thorax phantom, and this was compared with the dose distribution
on CT. This study has shown that the number of voxels that fail the
g-analysis with a 3%/3-mm criterion was less than 1%, and the
accuracy of the average dose in the target was also within 1%.
Recalculation of the treatment plans on CBCT was compared
with an estimation of the dose in the target and the OARs on the
basis of superposition of the original planned dose distribution on
CBCT geometry. In this approximation the dose was assumed to
be spatially invariant.
Analysis
We compared the volume of the ITV that received 100% of the
prescribed dose (V100%) of the recalculated dose distribution withthe V100% of the original plan. In the original treatment plans this
volume is 100% (i.e., 100% of the volume receives 100% of the
prescribed dose).
The V100% was correlated with the vector of the match result
Rmatch to determine the relation between the dose difference and
the set-up error.
RmatchZ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
M2LR þM2CC þM2DV
q
; ð1Þ
where MLR, MCC, and MDV were the match results in the
lefteright, craniocaudal, and dorsoventral directions, respectively.
For the OARs the difference of the maximum dose on the
CBCT and on the planning CT was analyzed. The reported
difference is the relative error with respect to the prescribed dose.
DDmaxð%ÞZDmax;CBCT Dmax;plan
PD
 100; ð2Þ
where DDmax is the relative difference of the maximum dose of
the OAR, Dmax,CBCT is the maximum dose of that OAR on the
CBCT, Dmax,plan is the maximum dose of the OAR in the treatment
plan, and PD is the prescribed dose. For the spinal cord Dmax is the
maximum dose in any point; for other OARs it is the maximum
dose in 1 cm3. The same formula is used for calculating the
relative difference while assuming an invariant dose. In that case
Dmax,plan is replaced by Dmax,invariant.
Results
Internal target volume
The V100% was determined by a full-dose recalculation using
a PTV margin of both 5 mm and 3 mm (Fig. 2a and b). Using the
CBCT before position correction, the V100% was 100% in 65% of
the cases when a 5-mm ITVePTV margin was used and 52%
when a 3-mm margin was used. After position correction this
amount improved to 98% and 96%, respectively, when margins of
5 mm and 3 mm were used. The V100% was expected to be lower
before correction with a 3-mm margin, because with smaller
margins underdosage will occur with smaller setup errors.
There was no strong correlation between Rmatch and V100%.
However, when the margin was used as a cutoff value there was
a significant difference in V100% between the groups. When
a margin of 5 mm was used, the mean value of V100% was 99.8%
(95% confidence interval (CI) 99.6%e99.9%) when Rmatch was
smaller than 5 mm and 89.5% (95% CI 82.2%e96.7%) when
Rmatch was larger than 5 mm (p < 0.001). When a margin of 3 mm
was used, the mean values were 99.6% (95% CI 99.4%e99.8%)
and 91.2% (95% CI 86.4%e96.0%) (p < 0.001). The means were
compared using the Mann-Whitney U test.
Organs at risk
The maximum dose of the OARs was determined in all fractions
and compared with the maximum dose in the treatment plan with
5-mm ITVePTV margins. The DDmax was in the range of 15%
to 10% before position correction (Fig. 3a) and after position
correction in the majority of the cases was within 5% (Fig. 3b).
The effect of the position correction was also within 5% for most
cases (Fig. 3c). A paired t test showed that the effect of the
position correction was statistically significant for the spinal cord
and the trachea, p Z 0.045 and p < 0.001, respectively.
Fig. 2. (a, b) Target coverage before and after correction (a) when an internal target volume (ITV)eplanning target volume margin of
5 mm is applied and (b) when a margin of 3 mm is applied. (c, d) V100% displayed as a function of Rmatch for (c) a 5-mm margin and
(d) a 3-mm margin.
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For 67% of the cases there was no difference in V100% of the ITV
between full recalculation and assuming an invariant dose distri-
bution DV100% (Fig. 4a). No differences occurred mainly for small
setup errors, whereby the assumption of invariant dose was more
likely to be correct. The errors increased with the setup errors
(Fig. 4b) because with large setup errors the beams will pass
through different body parts than planned. There was no clear
relation between DV100% and Rmatch, because there were also
other factors, for example a change in the shape of the patient, that
influence DV100%. When the margin was used as cutoff value, the
absolute value jDV100%j was significantly different between the
groups. The mean value of jDV100%j was 0.3% (95% CI 0.1%e
0.4%) when Rmatch was smaller than 5 mm and 3.3% (95% CIFig. 3. The DDmax in the organs at risk (a) before position correctio
position correction with DDmax before position correction. A paired t tes
The boundary of the box represents the 25th and 75th percentiles, the li
90th percentiles.2.0%e4.5%) when Rmatch was larger than 5 mm (p < 0.001). The
means were compared using the Mann-Whitney U test. For the
OARs the difference between full recalculation of the treatment
plan on CBCT and assuming an invariant dose distribution was up
to 8% (Fig. 5).
Errors due to moving OARs
The effect of improper placement of contours of OARs on the
CBCT set was estimated by moving the most critical OAR 5 mm
toward the target. The dose difference in this worst-case scenario
was up to 10%. The dose difference was higher when the “dose
before shift” was higher (Fig. 6). This was expected, because the
regions with a higher dose were associated with a steeper dose
gradient.n and (b) after position correction. (c) Difference of DDmax after
t shows a significant difference for the spinal cord and the trachea.
ne represents the median, and the whiskers represent the 10th and
Fig. 4. (a) Histogram of the relative difference between recalculation of the treatment plan based on cone-beam CT data and the dose
based on the assumption of an invariant dose distribution for the internal target volume. (b) Relative difference between recalculation and
assuming an invariant dose distribution for the internal target volume as a function of the match result.
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The goal of this study was to determine the benefits of DGRTwith
online dose recalculation for stereotactic lung irradiations. Dose-
guided radiotherapy can be used for online evaluation of the target
coverage and the maximum dose in the OARs. This can be very
helpful in the decision-making process in cases of substantial
changes in the patient’s geometry.
Recalculation of the treatment plan on CBCT was compared
with an estimation of the dose by superposition of the planned dose
on the CBCT dataset. In cases in which the setup error is large, the
estimation based on the planning CT can give wrong results. The
DDmax of the OARs is up to 8% when an invariant dose is used
instead of a recalculation. This clinically relevant error is probably
caused by a movement of the target with respect to the OARs.
Another reason for these differences is that with an invariant dose
changes in the patient shape are not taken into account.
In the case of SBRT for lung tumors, the contralateral part of
the body is often outside the reconstruction volume of the CBCT.
Irradiation of the contralateral lung is usually avoided. In this
study none of the beams entered through the missing part of the
body. However, this issue might be a limitation for applying
DGRT for other treatment sites.Fig. 5. Relative difference between full recalculation of the
treatment plan on cone-beam CT and assuming an invariant dose
distribution for the organs at risk. The boundary of the box
represents the 25th and 75th percentiles, the line represents the
median, and the whiskers represent the 10th and 90th percentiles.For the purpose of DGRT it is unrealistic to delineate all
structures manually. Therefore we copied the structures from the
planning CT and shifted them according to the match result. This
approximation might cause inaccuracies for the structures that are
not fixed to the bony anatomy, in this case the esophagus and the
trachea. Therefore we investigated a worst-case scenario on 10
scans to determine the error in the evaluated dose parameter, Dmax.
The error that was introduced was up to 10%, which is
a substantial error. This error increased when the maximum dose
increased, resulting in a larger error in the structure that was
already close to its critical dose. Note that in reality the error
would probably be smaller. We advise that when the dose in an
OAR is near the critical dose, to inspect whether the match is
correct and to adapt the delineation, when necessary. On the basis
of this information a decision on how to proceed can be made.
For the evaluation of the dose in the ITV, two treatment plans
were made, one with an ITVePTV margin of 5 mm and an
additional plan with a margin of 3 mm. We chose these margins
according to Hurkmans et al. (5), who recommend a 3e5-mm
margin when the ITV concept is used. In our study the ITV is
based on a slow CT, combined with a PET scan. The slow CT
takes 4 s per cycle and therefore risks missing a part of the tumor
when the patient’s breathing cycle is slower. The PET scan, on the
other hand, is truly a slow scan and will reveal possible under-
estimation of the ITV by the slow CT. Therefore our ITV volumes
are expected to be comparable to an ITV volume based onFig. 6. Difference in maximum dose in the esophagus and
trachea when a shift of 5 mm was applied in the direction of the
target. The DDmax is relative to the prescribed dose.
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a margin of 3 mm when a maximum intensity projection was used
for delineation, so the margin of 5 mm that we use clinically is on
the safe side. The acquisition time of a CBCT is 2 min, which
covers 20e30 breathing cycles, so there is no risk of partial miss
of tumor volume on CBCT scans.
Galerani et al. (10) also performed a retrospective dosimetric
analysis of the actual dose delivered to early-stage NSCLC
patients who were treated with SBRT. Their numbers are not
directly comparable to ours, because they calculated the difference
relative to the planned dose in that organ, whereas we calculated
the difference relative to the prescribed dose (Formula 2).
However, they also found clinically relevant changes of the dose
in the OARs. Therefore they advise to consider both the target and
the OAR in the process of image guidance in cases in which an
OAR is close to the target. No PRV margins were included in this
study to compensate for movement of OAR toward the target or
vice versa.
Our advice would be to use a PRV margin around each OAR
and make sure that the dose within that margin does not exceed
the tolerance dose of that OAR. This study shows that when a PRV
margin of 10 mm is used, DDmax in the OARs after position
correction is within 5% for the majority of the cases. In accor-
dance with Galerani et al. (10), we advise that the relative
movement of the target with respect to the OARs should be
considered during the image guidance procedure. In case of
doubts an online dose recalculation can be used to determine the
dose in that specific structure.
Dose-guided radiotherapy can also be used to determine
whether position correction is necessary. Our results imply that
with a 5-mm ITVePTV margin 65% of our position corrections
would not have been necessary, and with a 3-mm ITVePTV
margin this would be 52%. A position correction in our current
SBRT protocol takes approximately 5 to 6 min, because after the
table correction another CBCT scan is made and analyzed for
verification before the actual treatment is started. A prerequisite to
actually save time is that DGRT is considerably faster than that.
The calculation time in Oncentra for the collapsed cone algorithm
when graphics processing unit (GPU) enhancement is used takes
approximately 40e50 s. The body contour was delineated auto-
matically, but this still took a couple of minutes. The other
structures were copied from the planning CT. This makes sense,
because no large shape changes for the OARs are expected, and
tumor regression does not occur until the fourth week of treatment
(11), whereas our SBRT schedule for lung tumors takes 2 weeks at
the most. The workflow has to be optimized before the procedure
of DGRT will be an alternative for IGRT.Conclusion
Dose-guided radiotherapy can be a valuable addition to IGRT
because it enables evaluation of the dose in the target and the
OARs in cases of changes in the patient anatomy. The use of
DGRT is recommended in case of large anatomic changes or
a setup error larger than the margin.References
1. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase
II trial of medically inoperable stage I non-small-cell lung cancer
patients treated with stereotactic body radiotherapy. J Clin Oncol
2009;27:3290e3296.
2. Inoue T, Shimizu S, Onimaru R, et al. Clinical outcomes of stereo-
tactic body radiotherapy for small lung lesions clinically diagnosed as
primary lung cancer on radiologic examination. Int J Radiat Oncol
Biol Phys 2009;75:683e687.
3. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-
adapted fractionated stereotactic radiotherapy for stage I non-small-
cell lung cancer. Int J Radiat Oncol Biol Phys 2008;70:685e692.
4. Sonke JJ, Lebesque J, van Herk M. Variability of four-dimensional
computed tomography patient models. Int J Radiat Oncol Biol Phys
2008;70:590e598.
5. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommendations
for implementing stereotactic radiotherapy in peripheral stage IA non-
small cell lung cancer: Report from the Quality Assurance Working
Party of the randomised phase III ROSEL study.Radiat Oncol 2009;4:1.
6. Ahnesjo A. Collapsed cone convolution of radiant energy for photon
dose calculation in heterogeneous media. Med Phys 1989;16:
577e592.
7. Lehmann J, Perks J, Semon S, et al. Commissioning experience with
cone-beam computed tomography for image-guided radiation therapy.
J Appl Clin Med Phys 2007;8:2354.
8. Stippel G, van Rooijen D, Bel A. Robust automatic delineation of
body contours on cone-beam CT images. Proceedings of the XVIth
ICCR 2010. Electronic Publication.
9. Wang L, Hayes S, Paskalev K, et al. Dosimetric comparison of
stereotactic body radiotherapy using 4D CT and multiphase CT images
for treatment planning of lung cancer: Evaluation of the impact on
daily dose coverage. Radiother Oncol 2009;91:314e324.
10. Galerani AP, Grills I, Hugo G, et al. Dosimetric impact of online
correction via cone-beam CT-based image guidance for stereotactic
lung radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:1571e1578.
11. Underberg RW, Lagerwaard FJ, van Tinteren H, et al. Time trends
in target volumes for stage I non-small-cell lung cancer after
stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2006;64:
1221e1228.
